NCT00448097: Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy |
|
|
| Terminated | 2 | 7 | US | cetuximab, Erbitux, docetaxel, Taxotere | The Methodist Hospital Research Institute, Bristol-Myers Squibb, Eli Lilly and Company | Prostatic Neoplasms | 06/08 | 08/08 | | |
NCT00661492: Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) |
|
|
| Completed | 2 | 115 | US | cetuximab, Erbitux, Mitoxantrone, Novantrone | US Oncology Research, Eli Lilly and Company, Oregon Health and Science University | Androgen-independent Prostate Cancer | 03/11 | 06/11 | | |
